LEISH-F2 + MPL-SE

BIOLOGICAL2 trials

Sponsors

Access to Advanced Health Institute (AAHI), INFECTIOUS DISEASES RESEARCH INSTITUTE,

Conditions

Cutaneous Leishmaniasis

Phase 2

A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis

CompletedNCT01011309

Access to Advanced Health Institute (AAHI)Cutaneous Leishmaniasis

Start: 2009-10-31End: 2011-12-31Updated: 2013-12-11

Unknown Phase

A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis

Active, not recruitingPER-158-08

INFECTIOUS DISEASES RESEARCH INSTITUTE,

Target: 150Updated: 2023-09-04